Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.

Saved in:
Bibliographic Details
Title: Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.
Authors: Tariot PN; Banner Alzheimer's Institute, Phoenix, AZ, USA. Electronic address: pierre.tariot@bannerhealth.com., Lopera FS; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Ríos-Romenets S; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Sink KM; Genentech, San Francisco, CA, USA., Giraldo-Chica M; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Acosta-Baena N; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Villegas G; University of Antioquia, Medellín, Colombia., Espinosa A; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia; Hospital San Juan de Dios de Yarumal, Antioquia, Colombia., Castaño ML; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Muñoz C; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Ospina P; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Bocanegra Y; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Tirado V; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Henao E; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Cardona E; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Luna E; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Lopez H; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Sánchez G; Cardiomet Cequin, Universidad del Quindío, Armenia, Colombia; San Juan de Dios Hospital, Armenia, Colombia., Collazos MM; Marly's Clinic, Bogotá, Colombia., Alvarez S; Hospital Pablo Tobón Uribe, Medellín, Colombia., Aguillón D; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia., Hu N; Genentech, San Francisco, CA, USA., Clayton D; Genentech, San Francisco, CA, USA., Bittner T; Genentech, San Francisco, CA, USA; F Hoffmann-La Roche, Basel, Switzerland., Schneider A; F Hoffmann-La Roche, Basel, Switzerland., Dolton M; Genentech, San Francisco, CA, USA., Poon V; Genentech, San Francisco, CA, USA., Nguyen J; Genentech, San Francisco, CA, USA., Thomas RG; Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, San Diego, CA, USA., Schneider LS; Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA., Chen K; Banner Alzheimer's Institute, Phoenix, AZ, USA., Su Y; Banner Alzheimer's Institute, Phoenix, AZ, USA., Alexander RC; Banner Alzheimer's Institute, Phoenix, AZ, USA., Quiroz YT; Neuroscience Group of Antioquia (GNA), University of Antioquia, Medellín, Colombia; Departments of Psychiatry and Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, USA., Cai Y; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Xu YR; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Ostaszewski B; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Selkoe DJ; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Ashton NJ; Banner Alzheimer's Institute, Phoenix, AZ, USA; Banner Sun Health Research Institute, Sun City, AZ, USA; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Denkinger MN; Banner Sun Health Research Institute, Sun City, AZ, USA., Jakimovich LJ; Banner Alzheimer's Institute, Phoenix, AZ, USA., Doody RS; Genentech, San Francisco, CA, USA; F Hoffmann-La Roche, Basel, Switzerland., Langbaum JB; Banner Alzheimer's Institute, Phoenix, AZ, USA., Reiman EM; Banner Alzheimer's Institute, Phoenix, AZ, USA.
Source: The Lancet. Neurology [Lancet Neurol] 2026 Feb; Vol. 25 (2), pp. 147-159.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-4465
DOI:10.1016/S1474-4422(25)00426-0